2025/08/28 by Pamela Kushner, Carlos Campos, Aaron King +2 · 1 voice
Medicine · Biochemistry, Genetics and Molecular Biology · #Diabetes Treatment and Management #Metabolism, Diabetes, and Cancer #Pharmacology and Obesity Treatment
paper · pdf · doi:10.2337/cd25-0037
openalex publication_date 2025/08/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Glucagon-like peptide 1 (GLP-1) receptor agonists are prescribed as an adjunct to diet and exercise for the management of type 2 diabetes, yet adherence to healthy nutrition and physical activity is often suboptimal. As the use of these agents continues to rise, there are some concerns about the negative aspects of associated weight loss, including loss of muscle mass. This article highlights the benefits of healthy nutrition and physical activity for type 2 diabetes management irrespective of GLP-1 receptor agonist use or associated weight loss, identifies barriers to healthy nutrition and physical activity, and provides guidance for primary care clinicians to further educate and advise their patients on these important topics when initiating GLP-1 receptor agonist treatment.